Cihan TOP, Mehmet Emin ÖNDE, Özcan KESKİN, Bekir Yılmaz CİNGÖZBAY, Altuğ TUNCEL

Romatoid artritli hastalarda serum interleukin 1alfa düzeyleri ile insülin direnci arasındaki ilişki

Dolaşımdaki normal düzeylerde insüline hedef hücrenin cevabında bozulma olarak tanımlanan insülin direnci, sık rastlanan patolojik bir durumdur. Sitokinlerin insülin duyarlılığı üzerindeki potansiyel etkileri yoğun araştırmalara konu olmuştur. Bu çalışmanın amacı, romatoid artritli hastalarda insülin direnci gibi glukoz metabolizma anormallikleri ile serum interleukin 1. düzeyleri arasındaki bağlantıyı araştırmaktır. Çalışmaya değişik derecelerde hastalık aktivitesine sahip romatoid artritli 36 hasta (22 kadın ve 14 erkek, ortalama yaş: 51.5 ±17.1 yıl (21-80 yaş arası), ortalama VKİ: 27.1±5.0 kg/m²) ve yaş, cinsiyet, VKİ olarak benzer özelliklere sahip 20 sağlıklı kontrol dahil edilmiştir. Açlık serum IL-1 alfa ve insülin düzeyleri ölçüldü. İnsülin duyarlılığı HOMA yöntemiyle hesaplandı. Romatoid artritli hastalarda kontrollere oranla açlık serum insülin düzeyleri, HOMA skorları ve serum IL-1 alfa düzeyleri anlamlı derecede yüksekti (14.7±6.7, 8.7±1.9 µIU/ml, p

The serum interleukin 1 alfa levels in patients with rheumatoid arthritis and correlation with insulin resistance

Insulin resistance is a common pathological state in which target cells fail to respond to ordinary levels of circulating insulin. The cytokines are the subject of intense research for potential effects on insulin sensitivity. The aim of our study was evaluate the correlation of the changes in serum IL-1 alfa levels with glucose metabolism abnormality, such as insulin resistance, in patients with rheumatoid arthritis. In this study, 36 subjects (22 women and 14 men, aged 51.5 ±17.1 years, ranging between 21-80, BMI 27.1±5.0 kg/m²) with varying degrees of disease activity and a control group of 20 healthy subjects matched by age, sex, and body mass index were evaluated. The fasting serum IL-1 alfa and insulin levels were measured. HOMA-estimated insulin sensitivity was calculated. The fasting insulin levels, HOMA scores and serum IL-1 alfa levels were significantly higher in all patients with rheumatoid arthritis than in control subjects (14.7±6.7 vs. 8.7±1.9 µIU/ml, p

PDF

___

1. Gordon DA, Hastings DE: Rheumatology, second edition. in Klippel JH, Dieppe PA(eds): Rheumatoid arthritis, clinical features of early, progressive and late disease. London, 1998, 5:3.1-3.4s.
2. Matteson EJ, Cohen MD, Conn DL: Rheumatology, second edition. in Klippel JH, Dieppe PA(eds): Rheumatoid arthritis, clinical features and systemic involvment. London, 1998, 5:4.1- 4.8s.
3. Gaston H: Rheumatology, second edition. in Klippel JH, Dieppe PA(eds): Rheumatoid arthritis, cellular immunity in RA. London, 1998, 5:10.1-10.6s.
4. Bresnihan B: Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol 1999; 26: 717-9.
5. Wooley P: Rheumatology, second edition. in Klippel JH, Dieppe PA(eds): Rheumatoid arthritis, animal model of arthritis. London, 1998, 5:8.1-8.6s.
6. Virkamaki A, Ueki K, Kahn CR: Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 1999; 103: 931-43.
7. Roach P, Zick Y, Formisane P, Accili D, Taylor SI, Gorden P: A novel human IR gene mutation uniquely inhibits insulin binding without impairing posttranslational processing. Diabetes 43: 1096-1102, 1994.
8. Arnett FC, Edworthy SM, Bloch DA et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. J Rheumatol 1988; 31: 315- 24.
9. Matthews DR, Hosker JP, Turner RC: Homeostasis Model Assesment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
10. Matsuda M, DeFronzo RA:Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 1999, 22: 1462-70.
11. Genuth S, Brownlee MA, Kuller LH, Samols E, Saudek CD, Sherwin R: Consensus development conference on insülin resistance. Diabetes Care 1998; 21(2): 310.
12. Festa A, D’Agostino R, Hales CN, Mykanen L, Haffner SM: Heart rate in relation to insulin sensitivity and insulin secretion in nondiabetic subject. Diabetes Care 2000; 23: 624-8.
13. Haffner SM, Howard G, Mayer E, Bergman RN, Savage PJ, Rewers M, Mykanen L, Karter AJ, Hamman R, Saad MF: Insulin sensitivity and acute insulin response in Africans- Americans, Non-Hispanic Whites, and Hispanics with NIDDM: The Insulin Resistance Atherosclerosis Study. Diabetes 1997; 46: 63-9.
14. Svenson H: Insulin and atheroma 20 yrs perspective. Diabetes Care 1990; 13(6): 631-54.
15. Tanaka T, Itoh H, Doi K, Fukunaga Y, Hosoda K, Shintani M, Yamashita J, Chun TH, Inoue M, Masatsugu K, Sawada N, Saito T, Inoue G, Nishimura H, Yoshimasa Y, Nakao K: Down regulation of peroxisome proliferator-activated receptorgamma expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia 1999; 42(6):702-10.
16. Amrani A, Jafarian-Tehrani M, Mormede P, Durant S, Pleau JM, Haour F, Dardenne M, Homo-Delarche F: Interleukin-1 effect on glycemia in the non-obese diabetic mouse at the pre-diabetic stage. J Endocrinol 1996; 148(1): 139-48.
17. Ling PR, Istfan NW, Colon E, Bistrian BR: Differential effects of interleukin-1 receptor antagonist in cytokine- and endotoxintreated rats. Am J Physiol 1995; 268(2): E255-61.
18. Ling PR, Bistrian BR, Mendez B, Istfan NW: Effects of systemic infusions of endotoxin, tumor necrosis factor, and interleukin-1 on glucose metabolism in the rat: relationship to endogenous glucose production and peripheral tissue glucose uptake. Metabolism 1994; 43(3): 279-84.
19. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA: High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51: 455-61.
20. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP: The relation of markers of inflammation to the development of glucose disorders in the elderly: The Cardiovascular Health Study. Diabetes 2001; 50: 2384-9.
21. Festa A, D’Agostino R, Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 1131-7.
22. Thomas HE, Darwiche R, Corbett JA, Kay TWH: Interleukin-1 plus –γ-interferon-induced pancreatic ß-cell dysfunction is mediated by ß-cell nitric oxide production. Diabetes 2002; 51: 311-6.
23. Andersen HU, Jorgensen KH, Egeberg J, Mandrup-Poulsen T, Nerup J: Nicotinamide prevents interleukin-1 effects on accumulated insulin release and nitric oxide production in rat islets of Langerhans. Diabetes 1994; 43: 770-7.
24. McDaniel ML, Hughes JH, Wolf BA, Easom RA, Turk JW: Descriptive and mechanistic considerations of interleukin 1 and insulin secretion. Diabetes 1988; 37: 1311-5.
25. Comens PG, Wolf BA, Unanue ER, Lacy PE, McDaniel ML: Interleukin 1 is potent modulator of insulin secretion from isolated rat islets of Langerhans. Diabetes 1987; 36: 963-70.
26. Zawalich WS, Diaz VA: Interleukin 1 inhibits insulin secretion from isolated perifused rat islets. Diabetes 1986; 35(10): 1119-23.
27. Ma Z, Landt M, Bohrer A, Ramanadham S, Kipnis D M, Turk J: Interleukin-1 reduces the glycolytic utilization of glucose by pancreatic islets and reduces glucokinase mRNA content and protein synthesis by a nitric oxide-dependent mechanism. J Biol Chem 1997; 272 (28): 17827-35.
28. Ma Z, Ramanadham S, Corbett JA, Bohrer A, Gross RW, McDaniel ML, Turk J: Interleukin-1 enhances pancreatic islet arachidonic acid 12-lipoxygenase product generation by increasing substrate availability through a nitric oxide-dependent mechanism. J Biol Chem 1996; 271 (2): 1029-42.
29. Ohsumi J, Sakakibara S, Yamaguchi J, Miyadai K, Yoshioka S, Fujiwara T, Horikoshi H, Serizawa N: Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology 1994; 135(5): 2279-82.
30. Ji JD, Cheon H, Jun JB, Choi SJ, Kim YR, Lee YH, Kim TH, Chae IJ, Song GG, Yoo DH, Kim SY, Sohn J: Effects of peroxisome proliferator-activated receptor-gamma (PPARgamma) on the expression of inflammatory cytokines and apoptosis induction in rheumatoid synovial fibroblasts and monocytes. J Autoimmun 2001; 17(3): 215-21.